2013 first quarter activity
(Unaudited data)
thousands of euros
2012
2013
Variation at current exchange rates
Variation at constant exchange rates
France
74,188
84,720
+13.6%
+13.6%
International :
54,904
73,751
+34.3%
+35.0%
Incl. Europe excluding France
41,807
54,334
+30.0%
+30.4%
Incl. North America
10,285
15,562
+51.3%
+52.6%
Incl. Other countries
2,812
3,855
+37.1%
+39.4%
Group Total
129,092
158,021
+22.4%
+22.7%
thousands of euros
2012
2013
Variation at current exchange rates
Variation at constant exchange rates
Non-proprietary Homeopathic Medicines
73,427
79,062
+7.7%
+7.7%
OTC Specialties
55,576
78,866
+41.9%
+42.5%
Other
0,089
0,093
+4.5%
+3.4%
Group Total
129,092
158,021
+22.4%
+22.7%
HIGHLIGHTS OF FIRST QUARTER
The growth in sales revenues was highlighted by a high level of worldwide pathology and the impact of the prices increase in 2012 on certain non-proprietary homeopathic medicines in France. Such prices increase, for the most part, will only impact the first two months of 2013.
On March 31st 2013, the group's cash balance amounted to €121.5 million versus €94.7 million on December 31st 2012, which is linked to the increase of the business activity during the fourth quarter of 2012.
The U.S. subsidiary signed a settlement agreement aimed to put an end to the legal proceeding relating to Children's Coldcalm® medicine in California.
That agreement, which is subject to the court's approval, provides for:
a commitment to change the advertising and packaging within a time limit of 24 months from the court final approval,
bearing the legal expense of the opposing party,
the reimbursement, based solely on a claim-made process, to consumers who purchased the medicine in California.
It should be noted that a provision of 1 million US dollars was recorded for this litigation in 2011, which we still believe corresponds to the risk incurred.
Based on first-quarter performance, the group confirms its target of further increases in business and profitability in 2013.
Next updates:
May 23, 2013 at 10:30 am, at Boiron headquarters : 20 rue de la Libération, 69110 Sainte-Foy-lès-Lyon : Mixed General Meeting.
June 5, 2013, after the approval by the Mixed shareholders' Meeting, proposed dividend (0.90 € per share) will be paid out.
August 29, 2013, after the close of the stock market, publication of 2013 half-year financial information.
Financial information manager: Philippe MONTANT
Contact for financial information: Véronique BOUSCAYROL
Investor relations: +33 (0) 4.78.45.63.43 - e-mail: finances@boiron.fr
ISIN Code: FR0000061129 (BOI) - Bloomberg : BOI FP - Reuters : BOIR.PA
The group's financial information is online at : www.boiron.com
Communiqués au titre de l'obligation d'information permanente :
- Communiqué sur comptes, résultats, chiffres d'affaires
Communiqué intégral et original au format PDF :
http://www.actusnews.com/documents_communiques/ACTUS-0-31649-CP-BOIRON-230413.pdf
<!-- 90 -->
© Copyright Actusnews Wire
Recevez gratuitement par email les prochains communiqués de la société en vous inscrivant sur www.actusnews.com
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free